Week in Review: China's Innovent Raises $100 Million for Biologics Portfolio

Innovent Biologics of Suzhou announced a $100 million C round funding that will be used to advance the company's portfolio of eight biologic drug candidates; Hubei Biocause Pharma raised $1.6 billion in a private placement and will spend $1.2 billion to gain control of a life insurance company; Meinian Onehealth Healthcare, a Shanghai-based network of China clinics, invested in Ciming Health Checkup, a rival;  Kingworld Medicines will market Sinopharm products through e-business channels; Mitsubishi Gas Chemical and US-based Catalent Pharma formed an Asian biologics CRO partnership; PerkinElmer opened a medical lab in Suzhou to provide prenatal and infectious disease screening in China; the CFDA approved the world's first inactivated Sabin strain polio vaccine, developed by China's Institute of Medical Biology; and China's State Council, to improve rural healthcare in China, announced incentives for rural doctors and liberalized rules for private ownership of hospitals. More details.... Stock Symbols: (SHE: 000627) (HK: 1110) (NYSE: CTLT) (NYSE: PKI) Share this with colleagues: // //